Bipartisan congressional lawmakers are applauding the Food and Drug Administration (FDA) for releasing first-ever draft guidance on psychedelics research—a development that they had requested through a new bill just days before the agency took the step.
Reps. Dan Crenshaw (R-TX), Mariannette Miller-Meeks (R-IA) and Ro Khanna (D-CA) filed the legislation this month. And while FDA didn’t say that its decision to release the guidance was directly responsive to the measure, it’s precisely the action that the first part of the bill addressed.
“I’m glad the FDA is taking this first step of issuing guidance for psychedelic clinical trials—and listening to my bipartisan legislation with Reps. Miller-Meeks and Khanna,” Crenshaw said in a press release on Thursday. “It’s critical we get this right for the researchers doing this important scientific work.”
“We need this guidance to expand clinical trial access so that we can push towards life-saving psychedelic therapies for our veterans, servicemembers, and people living with PTSD, traumatic brain injury, and substance abuse disorder,” the congressman, a military veteran who has taken a leadership role on advancing psychedelics research, said.
FDA’s draft guidance provides scientists with a framework to carry out research that could lead to the development of psychedelic
Read full article on Marijuana Moment
